Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.

Panjwani N, Yoo CH, Wang E, Khodadoust MS, Kim YH, Hoppe RT, Hiniker SM.

J Dermatolog Treat. 2019 Jun 10:1-5. doi: 10.1080/09546634.2019.1628913. [Epub ahead of print]

PMID:
31179774
2.

Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.

Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004. Epub 2019 Mar 8.

PMID:
30858143
3.

Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs.

Obeid JP, Gutkin PM, Lewis J, Skinner L, Wang EB, Khodadoust MS, Kim YH, Weng WK, Hoppe RT, Hiniker SM.

Pract Radiat Oncol. 2019 Mar 2. pii: S1879-8500(19)30070-0. doi: 10.1016/j.prro.2019.02.016. [Epub ahead of print] No abstract available.

PMID:
30836188
4.

Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin.

Kheterpal MK, Dai J, Geller S, Pulitzer M, Ni A, Myskowski PL, Moskowitz A, Kim J, Hong EK, Fong S, Hoppe RT, Kim YH, Horwitz SM.

J Am Acad Dermatol. 2019 Jan 28. pii: S0190-9622(19)30144-6. doi: 10.1016/j.jaad.2019.01.037. [Epub ahead of print]

PMID:
30703460
5.

Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy.

Moding EJ, Advani R, Rosenberg SA, Hoppe RT.

Radiother Oncol. 2018 Dec;129(3):507-512. doi: 10.1016/j.radonc.2018.06.033. Epub 2018 Jul 6.

PMID:
30539763
6.

Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG.

Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG.

Blood. 2019 Jan 17;133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16.

PMID:
30446493
7.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R.

Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28.

PMID:
30154192
8.

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS.

Blood Adv. 2018 Jul 10;2(13):1547-1550. doi: 10.1182/bloodadvances.2018021071. No abstract available.

9.

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.

Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1100-1118. doi: 10.1016/j.ijrobp.2018.01.011. Epub 2018 Jan 9. Review.

10.

Post-treatment surveillance imaging in lymphoma.

Hiniker SM, Hoppe RT.

Semin Oncol. 2017 Oct;44(5):310-322. doi: 10.1053/j.seminoncol.2018.01.008. Epub 2018 Feb 3. Review.

PMID:
29580433
11.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N.

J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. doi: 10.6004/jnccn.2018.0013.

PMID:
29523663
12.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2018 Feb;16(2):123-135. doi: 10.6004/jnccn.2018.0007.

PMID:
29439173
13.

Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.

Tseng YD, Cutter DJ, Plastaras JP, Parikh RR, Cahlon O, Chuong MD, Dedeckova K, Khan MK, Lin SY, McGee LA, Shen EY, Terezakis SA, Badiyan SN, Kirova YM, Hoppe RT, Mendenhall NP, Pankuch M, Flampouri S, Ricardi U, Hoppe BS.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):825-842. doi: 10.1016/j.ijrobp.2017.05.004. Epub 2017 Sep 21. Review. No abstract available.

14.

Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG).

Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J.

Ann Oncol. 2017 Sep 1;28(9):2185-2190. doi: 10.1093/annonc/mdx334.

PMID:
28911068
15.

Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.

Amitay-Laish I, Sundram U, Hoppe RT, Hodak E, Medeiros BC, Kim YH.

JAAD Case Rep. 2017 Jul 19;3(4):310-315. doi: 10.1016/j.jdcr.2017.03.015. eCollection 2017 Jul. No abstract available.

16.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H.

J Natl Compr Canc Netw. 2017 May;15(5):608-638.

PMID:
28476741
17.

Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome.

Hoppe RT.

Oncol Res Treat. 2017;40(5):242-243. doi: 10.1159/000475528. Epub 2017 Apr 20. No abstract available.

18.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.

PMID:
28275031
19.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL.

J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw249. Print 2017 Apr. Review.

20.

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ.

Cancer Immunol Res. 2016 Nov;4(11):910-916. Epub 2016 Oct 13.

21.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P.

J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79.

PMID:
27587620
22.

Paediatric primary cutaneous marginal zone B-cell lymphoma: does it differ from its adult counterpart?

Amitay-Laish I, Tavallaee M, Kim J, Hoppe RT, Million L, Feinmesser M, Fenig E, Wolfe MEL, Hodak E, Kim YH.

Br J Dermatol. 2017 Apr;176(4):1010-1020. doi: 10.1111/bjd.14932. Epub 2017 Feb 20.

PMID:
27501236
23.

Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.

Million L, Yi EJ, Wu F, Von Eyben R, Campbell BA, Dabaja B, Tsang RW, Ng A, Wilson LD, Ricardi U, Kirova Y, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1454-1459. doi: 10.1016/j.ijrobp.2016.03.023. Epub 2016 Mar 24.

24.

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA.

J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.

25.

Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma.

Binkley MS, Hiniker SM, Donaldson SS, Hoppe RT.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):255-61. doi: 10.1016/j.prro.2015.11.013. Epub 2015 Nov 22.

PMID:
26935235
26.

Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era.

Ng AK, Dabaja BS, Hoppe RT, Illidge T, Yahalom J.

J Clin Oncol. 2016 May 1;34(13):1443-7. doi: 10.1200/JCO.2015.64.9418. Epub 2016 Feb 22. No abstract available.

PMID:
26903576
27.

Diffuse Large B-Cell Lymphoma Version 1.2016.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2016 Feb;14(2):196-231.

PMID:
26850490
28.

2 Gy × 2 for palliative treatment of mantle cell lymphoma.

White EC, Advani R, Hoppe RT.

Leuk Lymphoma. 2016 Sep;57(9):2219-21. doi: 10.3109/10428194.2015.1131274. Epub 2016 Jan 14. No abstract available.

PMID:
26763352
29.

Are Advanced Radiation Therapy Technologies Required for Treating Patients With Hodgkin Lymphoma?

Hoppe RT.

J Natl Compr Canc Netw. 2016 Jan;14(1):2-3. No abstract available.

PMID:
26733550
30.

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH.

J Clin Oncol. 2015 Nov 10;33(32):3766-73. doi: 10.1200/JCO.2015.61.7142. Epub 2015 Oct 5.

31.

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH.

Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7.

32.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM.

J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

33.

Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.

Iberri DJ, Hoppe RT, Advani RH.

Curr Treat Options Oncol. 2015 Sep;16(9):45. doi: 10.1007/s11864-015-0360-6. Review.

PMID:
26187795
34.

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.

Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH, Hoppe RT.

Leuk Lymphoma. 2016;57(3):604-8. doi: 10.3109/10428194.2015.1067700. Epub 2015 Aug 28.

PMID:
26159046
35.

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.

Advani RH, Hoppe RT.

Hematol Oncol. 2015 Jun;33 Suppl 1:90-5. doi: 10.1002/hon.2226. Review. No abstract available.

PMID:
26062064
36.

Hodgkin lymphoma, version 2.2015.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 May;13(5):554-86.

37.

Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using high-resolution array-based comparative genomic hybridization.

Weinberg OK, Ma L, Hoppe RT, Arber DA.

Am J Hematol. 2015 Aug;90(8):E151-2. doi: 10.1002/ajh.24050. Epub 2015 May 29. No abstract available.

38.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.

J Clin Oncol. 2015 Jun 10;33(17):1936-42. doi: 10.1200/JCO.2014.57.8138. Epub 2015 Apr 20.

39.

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

Hiniker SM, Pollom EL, Khodadoust MS, Kozak MM, Xu G, Quon A, Advani RH, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):99-106. doi: 10.1016/j.ijrobp.2015.01.039.

PMID:
25863757
40.

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

King MT, Donaldson SS, Link MP, Natkunam Y, Advani RH, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):67-75. doi: 10.1016/j.ijrobp.2015.02.001.

PMID:
25863755
41.

Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma.

Hoppe BS, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):40-5. doi: 10.1016/j.ijrobp.2015.02.008.

PMID:
25863752
42.

Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT; International Lymphoma Radiation Oncology Group.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):32-9. doi: 10.1016/j.ijrobp.2015.01.008.

43.

Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A; International Lymphoma Radiation Oncology Group.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):11-31. doi: 10.1016/j.ijrobp.2015.01.009.

44.

The Paris conference "La Radiothérapie de la Maladie de Hodgkin": a first step in the cure of Hodgkin disease.

Hoppe RT, Rosenberg SA.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):3-4. doi: 10.1016/j.ijrobp.2015.01.027. No abstract available.

PMID:
25863747
45.

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehension cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):326-62.

46.

Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials.

Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH.

J Am Acad Dermatol. 2015 Feb;72(2):286-92. doi: 10.1016/j.jaad.2014.10.014. Epub 2014 Dec 2.

PMID:
25476993
47.

Non-Hodgkin's lymphomas, version 4.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303.

48.

Non-Hodgkin's lymphomas, version 2.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2014 Jun;12(6):916-46.

PMID:
24925202
49.

Bulky mediastinal classical Hodgkin lymphoma in young women.

Percival ME, Hoppe RT, Advani RH.

Oncology (Williston Park). 2014 Mar;28(3):253-6, 258-60, C3. Review. No abstract available.

50.

Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.

Horst KC, Hancock SL, Ognibene G, Chen C, Advani RH, Rosenberg SA, Donaldson SS, Hoppe RT.

Ann Oncol. 2014 Apr;25(4):848-51. doi: 10.1093/annonc/mdu017. Epub 2014 Mar 7.

PMID:
24608191

Supplemental Content

Loading ...
Support Center